This led to the development and approval of third-generation EGFR TKIs like osimertinib, which are currently recommended for first-line use in patients with EGFR mutant NS-NSCLC with exon 19 deletion or L858R mutation [11]. Here, EGFR is linked to non-small cell lung carcinoma.